-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a new study, researchers have developed a cancer immunotherapy that combines ultrasound with cancer-killing immune cells to destroy malignant tumors while preserving normal tissues
This research solves a long-term problem in the field of cancer immunotherapy: how to make chimeric antigen receptor (CAR) T cell (CAR-T) therapy to treat solid tumors safely and effectively
CAR-T cell therapy is a promising new method for the treatment of cancer
CAR-T cell therapy is very effective in treating some blood cancers and lymphomas, but it has no effect on solid tumors
To solve this problem, these authors used standard CAR-T cells and redesigned them so that they only express CAR protein when ultrasonic energy is applied
The cancer immunotherapy developed by these authors involves injecting redesigned CAR-T cells into tumors in mice, and then placing a small ultrasound transducer on the skin area above the tumor to activate CAR-T cells
The in vitro function of CAR-T cells targeting prostate-specific membrane antigen (PSMA) induced by FUS series ultrasound.
These authors tested their CAR-T cells with standard CAR-T cells
However, this research is still in its early stages
Note: The original text has been deleted
Reference materials:
Yiqian Wu et al.